Keywords: Germany, Eliquis, Pfizer, Bristol-Myers, IQWiG, AMNOG, Thrombosis

German IQWiG finds mixed added benefits for Eliquis

Article | 02 April 2012

Print This

In an early benefit assessment under the Act on the Reform of the Market for Medicinal Products (AMNOG), the German ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in